Vaginal Atrophy (GSM): Causes, Symptoms, and Effective Treatments

Genitourinary Syndrome of Menopause (GSM), formerly vaginal atrophy, results from estrogen decline causing vulvovaginal thinning, dryness, and urinary symptoms. Affects ~50–70% of postmenopausal women; also occurs with breastfeeding, anti-estrogen therapy, or surgical menopause.

Symptoms

  • Vaginal dryness, burning, itching, irritation
  • Dyspareunia (painful intercourse), post-coital bleeding
  • Urinary urgency, frequency, dysuria, recurrent UTIs
  • Reduced lubrication, loss of elasticity, pallor/friability on exam

Treatment Options

Non-Hormonal (First-Line for Many)

  • Vaginal moisturizers (regular use, e.g., hyaluronic acid, polycarbophil)
  • Lubricants for intercourse (water/silicone-based)
  • Pelvic floor physical therapy

Local Estrogen (Gold Standard for Moderate-Severe)

  • Low-dose vaginal estradiol: cream, tablet (Vagifem), ring (Estring), insert (Imvexxy).
  • Minimal systemic absorption; safe for most (including many breast cancer survivors — oncologist consult).
  • Improves thickness, elasticity, pH, microbiome; reduces UTIs.

Systemic Hormone Therapy

If systemic symptoms (hot flashes, bone protection) also present; individualized risk/benefit.

Emerging

  • Ospemifene (oral SERM) for dyspareunia.
  • Laser/RF (fractional CO₂, Erbium:YAG, radiofrequency) — limited long-term data; not FDA-approved for GSM.

Prevention & Maintenance

  • Regular sexual activity/stimulation maintains tissue health.
  • Avoid irritants (scented products, douches).
  • Weight management, smoking cessation, pelvic floor exercises.

Discuss options with a menopause-informed clinician. GSM is treatable—don't suffer silently.

Urinary Disorders - Related Articles